Xilis, founded in 2019 and headquartered in the United States, is pioneering in the fields of Biotechnology, Health Care, Life Sciences, and Pharmaceutical industries. The company's slogan, "Next generation technologies for precision medicine," encapsulates its mission to revolutionize precision medicine and drug discovery.
In its relatively brief existence, Xilis has already garnered significant attention and financial backing. In a substantial $19.00M Series A round on 13 July 2022, the company attracted a diverse array of esteemed investors including Two Sigma Ventures, Felicis Ventures, GV, Duke Angel Network, Alexandria Venture Investments, Alix Ventures, Catalio Capital Management, EQT, FPV Ventures, and Mubadala Capital Ventures.
The combination of cutting-edge technology and robust financial support positions Xilis as an exciting prospect in the evolving landscape of precision medicine.